FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Friday

 

German pharma makes progress in new drugs to treat multiple sclerosis

(Posted By: Josi Creek)

“Multiple sclerosis patients can look forward to significant improvements in the treatment of the disease,” said Cornelia Yzer, general manager of the VFA, the German research-based pharmaceutical industry association. Ms Yzer’s speech marked this week’s World Multiple Sclerosis Day.




Read more »

Labels:


Thursday

 

Lifetime cost of multiple sclerosis: $1.2 million per patient

(Posted By: Josi Creek)


In honor of World MS Day, the Multiple Sclerosis International Federation has released a report on the economic impact of the disabling autoimmune disease. Based on data from 15 countries, the report shows the average lifetime cost of MS is $1.2 million per patient - and "loss of employment, or early retirement, is considered the single largest cost factor contributing to this financial cost."




Read more »

 

Biogen Idec Globally Commemorates Annual World MS Day


(Posted By: Josi Creek)

 On May 26, Biogen Idec  will join the global multiple sclerosis (MS) community to commemorate the second annual World MS Day. Biogen Idec is a leader in the fight against MS, bringing hope to the thousands of patients across the globe who benefit from the company's MS therapies and ongoing research programs.
World MS Day was established by the Multiple Sclerosis International Federation to raise awareness of MS, national MS societies and those living with and affected by MS, to unite, broaden and mobilize the community and to support MS-directed fundraising. This year's World MS Day focuses on raising awareness of employment issues amongst those who are living with MS.
Read more »

Labels:


 

A study On Fatigue in multiple sclerosis

(Posted By: Josi Creek)

Labels:


 

Study: Deep brain stimulation very good outcome for most patients with dystonia and tremor

(Posted By: Josi Creek)

Labels:


Monday

 

Low Prenatal Sunlight Exposure May Increase Multiple Sclerosis Risk

(Posted By: Josi Creek)

Low maternal exposure to sunlight during the first trimester of pregnancy may increase the risk of offspring later developing multiple sclerosis (MS), a new Australian study suggests.



Read more »

 

Biogen Idec and Abbott Announce Enrollment of First Patient in Study of Daclizumab for Relapsing-Remitting Multiple Sclerosis

(Posted By: Josi Creek)


Biogen Idec and Abbott today announced enrollment of the first patient in a global Phase III study evaluating the efficacy and safety of daclizumab compared to interferon beta-1a (AVONEX(R)) in patients with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). The trial, called DECIDE, will investigate a subcutaneous formulation of daclizumab intended for monthly administration, which has the potential to provide a new immunomodulatory approach for treating MS. Under the terms of the collaboration agreement, Biogen Idec will make a $30 million milestone payment to Abbott. This payment is due upon enrollment of the first patient in the DECIDE trial.
Read more »

Labels: , , ,


Friday

 

Cannabis-based Sativex Multiple Sclerosis treatment set for UK approval

(Posted By: Josi Creek)


Sativex, a ground-breaking cannabis-based drug for treating symptoms of multiple sclerosis (MS), could be approved in the UK by the end of June, its creator said on Thursday.


Read more »

Labels: ,


 

Roche And Biogen Idec To Discontinue Ocrelizumab Clinical Development for Patients With Rheumatoid Arthritis


(Posted By: Josi Creek)



Read more »

Labels:


Thursday

 

15-year follow-up study on Intramuscular Interferon

(Posted By: Josi Creek)

Labels:


Wednesday

 

A Study: Autoimmune Diseases prior to Multiple Sclerosis Diagnosis

(Posted By: Josi Creek)

Labels:


 

Alzheimer's Drug Trial On Multiple Sclerosis Patients for Cognitive Impairment

(Posted By: Josi Creek)

Labels: ,


 

A Study On The Probability of Divorce in Multiple Sclerosis Patients

(Posted By: Josi Creek)

Labels:


Tuesday

 

Acorda Therapeutics (Amprya) Recognized by National Organization for Rare Disorders for Contribution to Treatment of Multiple Sclerosis

Acorda Therapeutics, Inc. today announced the National Organization for Rare Disorders (NORD) is recognizing the Company for its efforts to develop therapies for rare diseases. Earlier this year, Acorda received approval from the U.S. Food and Drug Administration (FDA) for AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, the first therapy to improve walking in people with multiple sclerosis (MS). This was demonstrated by an improvement in walking speed. The award will be presented tonight at the 2010 NORD Partners in Progress Gala in Washington, D.C.

Read more »

Labels:


 

New Clinical Trial Of Investigational Multiple Sclerosis Treatment


(Posted By: Josi Creek)

Read more »

Sunday

 

Researchers seeking 1,000 who have Multiple Sclerosis

(Posted By: Josi Creek)

Duke University's medical research study at the N.C. Research Campus will recruit 1,000 people with multiple sclerosis to better understand how the unpredictable neurological disease progresses.

Ultimately, researchers want to find a cure for MS, which afflicts 400,000 Americans.




Read more »

Friday

 

A Study: Copaxone (glatiramer acetate) Does not show significant affect on on Multiple Sclerosis Progression: Not affective for progressive forms

(Posted By: Josi Creek)

Labels:


 

FDA denies Teva bid to block generic Copaxone

(Posted By: Josi Creek)

The US Food and Drug Administration has once again rejected Teva Pharmaceutical Industries’ request to stop approval of any generic versions of the Israeli company’s multiple sclerosis blockbuster Copaxone.



Read more »

Labels:


Thursday

 

A study: Case of Long survival and clinical stability in Deadly variant of multiple sclerosis

(Posted By: Josi Creek)


 "Marburg's variant multiple sclerosis is an acute and aggressive atypical form of MS, leading frequently to death in few months. "



Labels:


Wednesday

 

FDA To Target Misleading Drug Ads

(Posted By: Josi Creek)

"Last month, FDA sent a warning letter to Biogen Idec, Inc., for downplaying the risks of progressive multifocal leukoencephalopathy (PML), a rare, but often fatal, brain infection that has been linked to the multiple sclerosis drug Tysabri. The statements were made in a series of webcasts used to promote the drug between late October and early November of 2009."
Federal drug regulators are hoping to recruit doctors in the hunt for misleading drug advertisements through a new initiative aimed at marketing materials that provide inaccurate or misleading information, or make statements that downplay or omit the negative side effects of drugs.

Read more »

Labels: , ,


 

Repeat Rituxan ( Rituximab) Therapy Helps in Resistant Rhumatoid Arthritis

(Posted By: Josi Creek)

Most patients with resistant rheumatoid arthritis who failed to respond to an initial cycle of rituximab (Rituxan) showed clinical improvement following a second treatment cycle, a British study found.


I wonder how this will effect those with MS who are taking Rituxan. Perhaps the results of this study show promise for both Multiple Sclerosis and Rhumatoid Arthritis patients.






Read more »

Labels: , ,


 

Study to Examine Emotional side of Multiple Sclerosis Looking For Participants

(Posted By: Josi Creek)



How do people with multiple sclerosis emotionally adjust to living with the debilitating disease?

That's the focus of a study by Melissa Kehler, a University of Regina doctoral psychology student, who is looking for 400 adult Canadians with MS to complete a one-time questionnaire that is available either online or in paper format.



Read more »

 

Liberation Procedure (CCSVI) for Multiple Sclerosis lands Victoria BC surgeon in hot water

(Posted By: Josi Creek)


The B.C. woman who had the experimental neck vein procedure defends the treatment



Read more »

Labels: ,


Tuesday

 

A Study: Health Toll On the Multiple Sclerosis Caregivers; What can be Done

(Posted By: Josi Creek)

Labels:


 

Zebrafish may hold the Key to Restoring Myelin

(Posted By: Josi Creek)

 

A Medical Publication: Genes may play a role in Multiple Sclerosis patients response to Interfrerons

(Posted By: Josi Creek)

Labels:


 

A study: additional eye damage in multiple sclerosis patients with or without optic neuritis

(Posted By: Josi Creek)

Labels:


 

BERLENA HAS PHOTOS & AN AMAZING STORY ABOUT HOW AMPYRA HELPED HER WALKING ON HER CRUISE!

(Posted By: Josi Creek)

CLICK HERE TO GO TO OUR FACEBOOK PAGE & READ COMMENTS & (((HUGS)) OUR Facebook FRIENDS LEFT FOR
!


Stan, This is a comment my son made after looking at one of our pictures taken on the cruise ......... "Where did you take this?!?"! LOL! Very nice! I always enjoy hangin out with you and Pops...Broham (Pops) is finally coming around!...As for you, I'm so glad that you continue to take things in stride and don't let things stop you!....Just like a true Spencer!...Luv ya both!
Read more »

Labels:


 

Tysabri (natalizumab) may interfere with central nervous system immune surveillance.

A study about the immune system of the central nervous system itself, and how it is negatively affected by Tysabri.  Could this could lead to further explinations for the cause of the many cases of PML?

Labels: , ,


 

A Case of Hydrocephalus during Natalizumab (Tysabri) treatment.

(Posted By: Josi Creek)

The headline of this story links to a medical publication of a case involving a woman suffering from multiple sclerosis who experienced an acute tetra-ventricular hydrocephalus soon after the beginning of immunomodulating treatment with natalizumab (Tysabri).






Labels: ,


 

Celebrities lend their support to Multiple Sclerosis survivor and advocate Nancy Davis

(Posted By: Josi Creek)


Avril Lavigne, Tia Carrere and Tom Arnold are just several of the celebrities lending their support to Multiple Sclerosis (MS) survivor and advocate Nancy Davis for May’s MS Awareness Month.





Read more »

Labels:


Monday

 

1.9 Million Dollar grant to help researchers explore new ways to reverse myelin damage caused by multiple sclerosis

(Posted By: Josi Creek)

About 400,000 Americans and about 2.5 million people worldwide suffer from MS, according to the National Multiple Sclerosis Society. The drugs that are available now focus mainly on controlling the inflammatory nature of the diseases to limit the development of neuronal damage. They do not reverse the damage caused by the disease. This research could lead to a huge medical breakthrough in the treatment of multiple sclerosis as well as other neurological conditions.




Read more »

 

Elan Corp., which manufactures Tysabri, halts Alzheimer's drug clinical trial after 9 deaths

(Posted By: Josi Creek)


Although this isn't directly related to Multiple Sclerosis, I feel this article is important due to the trouble that has been surrounding Tysabri. Recently they were cited for a misleading video about their product (Tysabri), which grossly underestimated the risks associated with the drug, and most recently had to update the safety label of Tysabri after studies showed a heightened risk of death among patients taking it.  Some alzheimer's medications have been used in the past for cognitive problems associated with MS.




Read more »

Labels: ,


Sunday

 

Variants of gene associated with multiple sclerosis found!

(Posted By: Josi Creek)

Read more »

Labels:


Saturday

 

New Compound Stabilizes 100 percent of Multiple Sclerosis Patients in study

(Posted By: Josi Creek)


Read more »

Friday

 

Woman to celebrate her 83rd birthday by throwing herself from a plane for Multiple Sclerosis (Scotland)

(Posted By: Josi Creek)


Read more »

 

Demyelination as a complication of new immunomodulatory treatments.

(Posted By: Josi Creek)

Labels:


 

Long term treatment with interferon-beta slows progression in multiple sclerosis as well as time to conversion to secondary progressive multiple sclerosis.

(Posted By: Josi Creek)

Labels:


 

Evaluating loss of visual function in multiple sclerosis as measured by low-contrast letter acuity.

(Posted By: Josi Creek)

Labels:


 

Patient-centered outcomes becoming increasingly important in evaluations of MS therapies

(Posted By: Josi Creek)

Labels:


 

Future research should be directed at determining the significance of freedom from disease activity during a clinical trial in relapsing-remitting MS

(Posted By: Josi Creek)


Labels:


 

A better test that clinically measures Multiple Sclerosis disability?

This test provides a focused and sensitive evaluation of disability in patients with multiple sclerosis that may be more responsive to change than that provided by the Expanded Disability Status Scale. The article I have just posted suggests  that uture research should be directed at adding a test that measures visual function (e.g., contrast acuity), at replacing the PASAT by a cognition test that has better measurement characteristics, and at developing methods to better understand the clinical relevance of changes in MSFC scores.
(Comment &  Post by: Josi Creek)

Read more »

Labels:


 

Vitamin D deficiency seems to be involved in the patho-immunological process of multiple sclerosis.

(Posted By: Josi Creek)

Labels:


 

Study finds no differences fMRI scanning of working memory tasks between Multiple Sclerosis patients and control subjects

(Posted By: Josi Creek)

Labels:


 

Findings suggest that many Multiple Sclerosis patients suffer from various forms of Malnutrition.

(Posted By: Josi Creek)

Labels:


 

The lonely battle for dignity: individuals struggling with multiple sclerosis.

(Posted By: Josi Creek)

Labels:


 

Oral cladribine and fingolimod for relapsing multiple sclerosis.

(Posted By: Josi Creek)

Labels: , ,


 

Pulse methylprednisolone therapy may reduce the risk of developing NAbs

(Posted By: Josi Creek)

Labels:


 

Modern imaging techniques; neuropathological examinations showed that more than myelin is damaged in Multiple Sclerosis patients.

(Posted By: Josi Creek)

Labels:


 

Ability to make decisions about medical treatment compromised in Multiple Sclerosis Patients

(Posted By: Josi Creek)

Labels:


Thursday

 

Biomedical scientists 'encouraged by Multiple Sclerosis stem cell trials'

(Posted By: Josi Creek)


Read more »

Labels: ,


Tuesday

 

Recent study shows smoking increases the risk of multiple sclerosis

(Posted By: Josi Creek)

Read more »

 

Acorda Therapeutics Chief Executive Officer Ron Cohen Elected Chairman of BIO Emerging Companies Section

(Posted By: Josi Creek)


Read more »

 

U.S. Health Reform Seen as ‘Opportunity;Teva (Copaxone) Profit Rises 31%

(Posted By: Josi Creek)

Read more »

Labels:


Saturday

 

What's new in Various Medical Publications

 

What's new on Multiple Sclerosis on PubMed

( Posted by-Desinie Smith)
In this issue.

Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases.Muramatsu T.

Validation of the CD6 and TNFRSF1A loci as risk factors for multiple sclerosis in Spain.Swaminathan B, Matesanz F, Cavanillas ML, Alloza I, Otaegui D, Olascoaga J, Cénit MC, Heras VD, Barcina MG, Arroyo R, Alcina A, Fernandez O, Antigüedad A, Urcelay E, Vandenbroeck K.

[Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs]
[Article in German]
Hecht B.

Labels:


 

Gene Study Allows for Environmental Explanation of MS

(Posted by-Desinie Smith)

Labels:


 

Low maternal exposure to ultraviolet radiation in pregnancy, month of birth, and risk of multiple sclerosis in offspring: longitudinal analysis

( Posted by-Desinie Smith)

Labels:


 

New finding paves way for diagnosis of multiple sclerosis before it strikes

(Posted by-Desinie Smith)

Labels:



Go to Newer News Go to Older News